Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors.

Osimertinib, a third-generation EGFR-tyrosine kinase inhibitor, is the first-line therapy for lung cancer harboring EGFR mutations. The mechanisms underlying osimertinib resistance are diverse, with approximately half remaining unknown. Epigenetic dysregulation is implicated in drug resistance; however, the mechanisms remain unclear.

Clinical significance of 4 L lymphadenectomy in solid dominant clinical stage I non-small cell lung cancer in the left upper lobe.

Objectives: The significance of station 4 L lymph node dissection (LND) for early-stage non-small cell lung cancer (NSCLC) is unknown.

Methods: We evaluated 342 patients who underwent complete anatomical resection and mediastinal LND for radiologically solid dominant clinical (c)-Stage I left upper lobe NSCLC between 2008 and 2022. Solid dominant was defined as a consolidation tumor ratio >0.

Effect of ground-glass opacity components on the recurrence of pathological stage IB non-small cell lung cancer harboring epidermal growth factor receptor mutations.

Purpose: This study aimed to examine the influence of ground-glass opacity (GGO) on the prognosis of epidermal growth factor receptor (EGFR)-mutated pathological (p)-stage IB non-small cell lung cancer (NSCLC).

Methods: Between 2009 and 2021, 115 patients underwent complete anatomical lung resection with mediastinal lymphadenectomy for p-stage IB non-squamous NSCLC harboring common EGFR mutations. The patients were classified into the part-solid and pure-solid arms based on the presence of GGO components.

Six radical surgeries for metachronous multiple primary lung cancer: A case report.

Introduction And Importance: Comprehensive reports on surgery for metachronous multiple primary lung cancers after the third or subsequent surgeries are lacking. Herein, we report a case in which six radical surgeries were performed for metachronous primary lung cancer.

Case Presentation: The patient was a 62-year-old man when he underwent his first surgery, a right lower lobectomy, and the pathological diagnosis was adenocarcinoma.

Autologous Rib Grafts for Sternal Reconstruction After Excision of a Chondrosarcoma.

Sternal chondrosarcoma is a rare malignant condition. Although surgical resection is crucial, the reconstruction of sternal defects is challenging. A 64-year-old male patient with a history of 2 separate sternal tumor resections received a diagnosis of sternal chondrosarcoma recurrence.